HEALY JAMES — SEC Form 4 filings
SEC reporting owner CIK 1245624. 21 Form 4 filings on record with FilingPulse; latest filed 2026-06-12.
Transaction summary — filings shown
Covers all 21 filings on record, filed 2024-01-30 to 2026-06-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 23 legs across 4 filings — 1,713,965 shares, $30,579,545 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 47.
- Largest priced transaction: purchase of 588,888 shares @ $18.00 ($10,599,984) in BioAge Labs, Inc., filed 2024-09-27.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | Director | 3 | 5 legs · 666,665 sh · $11,999,970 | — | 5 |
| Rapport Therapeutics, Inc. (RAPP) | Director | 4 | 17 legs · 602,856 sh · $10,579,583 | — | 4 |
| ArriVent Biopharma, Inc. (AVBP) | Director | 1 | 1 leg · 444,444 sh · $7,999,992 | — | 2 |
| Y-mAbs Therapeutics, Inc. (YMAB) | Director | 3 | — | — | 15 |
| Karuna Therapeutics, Inc. (KRTX) | Director | 1 | — | — | 9 |
| Natera, Inc. (NTRA) | Director | 7 | — | — | 7 |
| Seaport Therapeutics, Inc. (SPTX) | Director | 1 | — | — | 4 |
| Bolt Biotherapeutics, Inc. (BOLT) | Director | 1 | — | — | 1 |
Form 4 filings — HEALY JAMES
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-12 | 4 | BioAge Labs, Inc. (BIOA) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Rapport Therapeutics, Inc. (RAPP) | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Seaport Therapeutics, Inc. (SPTX) | Conversion (C): 1,927,159 · Conversion (C): 804,379 · Conversion (C): 6,052,631 (derivative) @ $0 · Conversion (C): 2,526,315 (derivative) @ $0 | EDGAR |
| 2025-09-18 | 4 | Y-mAbs Therapeutics, Inc. (YMAB) | Code (U): 31,603 @ $8.60 · Disposition to issuer (D): 25,080 · Code (U): 2,194,278 @ $8.60 · Disposition to issuer (D): 14,222 (derivative) · Disposition to issuer (D): 8,000 (derivative) · Disposition to issuer (D): 11,000 (derivative) · +5 more | EDGAR |
| 2025-07-02 | 4 | Y-mAbs Therapeutics, Inc. (YMAB) | Grant/award (A): 25,080 @ $0 · Grant/award (A): 33,450 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Rapport Therapeutics, Inc. (RAPP) | Grant/award (A): 21,850 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | BioAge Labs, Inc. (BIOA) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-04-29 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 142 | EDGAR |
| 2025-02-04 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 114 | EDGAR |
| 2024-10-29 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 153 | EDGAR |
| 2024-09-27 | 4 | BioAge Labs, Inc. (BIOA) | Conversion (C): 1,638,236 · Purchase (P): 588,888 @ $18 · Purchase (P): 11,113 @ $18 · Purchase (P): 18,353 @ $18 · Purchase (P): 21,814 @ $18 · Purchase (P): 26,497 @ $18 · +2 more | EDGAR |
| 2024-07-30 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 177 | EDGAR |
| 2024-07-03 | 4 | Rapport Therapeutics, Inc. (RAPP) | Purchase (P): 3,538 @ $23.08 · Purchase (P): 3,565 @ $24.21 · Purchase (P): 4,544 @ $25.02 · Purchase (P): 2,559 @ $26.06 · Purchase (P): 3,799 @ $23.08 · Purchase (P): 3,828 @ $24.21 · +6 more | EDGAR |
| 2024-07-02 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 2,964 | EDGAR |
| 2024-06-14 | 4 | Bolt Biotherapeutics, Inc. (BOLT) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Y-mAbs Therapeutics, Inc. (YMAB) | Grant/award (A): 3,495 @ $0 · Grant/award (A): 14,545 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Rapport Therapeutics, Inc. (RAPP) | Conversion (C): 1,392,738 @ $0 · Purchase (P): 470,589 @ $17 · Purchase (P): 18,641 @ $17 · Purchase (P): 17,861 @ $17 · Purchase (P): 26,278 @ $17 · Purchase (P): 25,455 @ $17 · +1 more | EDGAR |
| 2024-04-30 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 210 | EDGAR |
| 2024-03-18 | 4 | Karuna Therapeutics, Inc. (KRTX) | Disposition to issuer (D): 32,500 @ $330 · Disposition to issuer (D): 990 @ $330 · Disposition to issuer (D): 683 @ $330 · Disposition to issuer (D): 1,372,441 @ $330 · Disposition to issuer (D): 8,025 @ $330 · Disposition to issuer (D): 12,500 (derivative) @ $232.41 · +3 more | EDGAR |
| 2024-01-31 | 4 | ArriVent Biopharma, Inc. (AVBP) | Conversion (C): 1,252,308 · Purchase (P): 444,444 @ $18 · Conversion (C): 1,252,308 (derivative) | EDGAR |
| 2024-01-30 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 264 @ $63.79 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1245624 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →